The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials

Clinical Therapeutics

Volumn 34, Issue 5, 2012, Pages 1056-1069

  Cornblath, David R ^a   Bienen, Jay E ^b   Blight, Andrew R ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Curry Rockefeller Group   (United States)

^c ACORDA THERAPEUTICS INC   (United States)

Author keywords

4 aminopyridine; Dalfampridine; Fampridine; Multiple sclerosis; Safety

Indexed keywords

4 AMINOPYRIDINE; BACLOFEN; BETA1A INTERFERON; CANNABIS; CYTOCHROME P450 2E1; INTERFERON BETA SERINE; MOXIFLOXACIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; STEROID; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BALANCE DISORDER; BLADDER DYSFUNCTION; BLURRED VISION; CELLULITIS; CHOLELITHIASIS; COMPLEX PARTIAL SEIZURE; CONFUSION; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIAPHORESIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXPANDED DISABILITY STATUS SCALE; FALLING; FOCAL EPILEPSY; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GRAND MAL SEIZURE; HEADACHE; HEART ARRHYTHMIA; HEART RATE; HUMAN; HYPERTENSION; IC 50; INFESTATION; INSOMNIA; KIDNEY DYSFUNCTION; LIMB PAIN; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MENTAL HEALTH; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PARESTHESIA; PATELLA FRACTURE; PERIPHERAL EDEMA; PNEUMONIA; PR INTERVAL; PYELONEPHRITIS; QRS COMPLEX; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RHINOPHARYNGITIS; SEIZURE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SPASTICITY; SPINAL CORD INJURY; SUDDEN DEATH; SYNCOPE; SYSTEMATIC REVIEW; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

4-AMINOPYRIDINE; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS; TABLETS; WALKING;

EID: 84860755679     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.03.007     Document Type: Review

References (89)

1. ® [dalfampridine] extended release tablets [prescribing information] January 2010, Acorda Therapeutics Inc, Hawthorne, NY.
2. Goodman A.D., Cohen J.A., Cross A., et al. Fampridine-SR in multiple sclerosis: a randomized, double blind, placebo-controlled, dose-ranging study. Mult Scler 2007, 13:357-368.
3. Goodman A.D., Brown T.R., Cohen J.A., et al. Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008, 71:1134-1141.
4. Goodman A.D., Brown T.R., Krupp L., et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373:732-738.
5. Goodman A.D., Brown T.R., Edwards K.R., et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010, 68:494-502.
6. Gold M.S., Shuster M.J., Levine J.D. Characterization of six voltage-gated K+ currents in adult rat sensory neurons. J Neurophysiol 1996, 75:2629-2646.
7. Coetzee W.A., Amarillo Y., Chiu J., et al. Molecular diversity of K+ channels. Ann N Y Acad Sci 1999, 868:233-285.
8. v channels and effects of symptomatic treatment. Pharmacol Ther 2006, 111:224-259.
9. Sherratt R.M., Bostock H., Sears T.A. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980, 283:570-572.
10. Targ E.F., Kocsis J.D. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985, 328:358-361.
11. Blight A.R. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989, 22:47-52.
12. Shi R., Blight A.R. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997, 77:553-562.
13. Lundh H. Effects of 4-aminopyridine on neuromuscular transmission. Brain Res 1978, 153:307-318.
14. Kim Y.I., Goldner M.M., Sanders D.B. Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states. Muscle Nerve 1980, 3:112-119.
15. Smith K.J., Felts P.A., John G.R. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000, 123:171-184.
16. Lundh H., Nilsson O., Rosén I. Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry 1979, 42:171-175.
17. Lundh H., Nilsson O., Rosén I. 4-aminopyridine: a new drug tested in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry 1977, 40:1109-1112.
18. Agoston S., van Weerden T., Westra P., et al. Effects of 4-aminopyridine in Eaton Lambert Syndrome. Br J Anaesth 1978, 50:383-385.
19. Strupp M., Kalla R., Dichgans M., et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004, 62:1623-1625.
20. Glasauer S., Kalla R., Büttner U., et al. 4-aminopyridine restores visual ocular motor function in upbeat nystagmus. J Neurol Neurosurg Psychiatry 2005, 76:451-453.
21. Glasauer S., Büttner U., Brandt T., et al. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 2007, 130:2441-2451.
22. Hansebout R.R., Blight A.R., Fawcett S., et al. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993, 10:1-18.
23. Potter P.J., Hayes K.C., Hsieh J.T., et al. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases. Spinal Cord 1998, 36:147-155.
24. Segal J.L., Pathak M.S., Hernandez J.P., et al. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 1999, 19:713-723.
25. van der Bruggen M.A., Huisman H.B., Beckerman H., et al. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 2001, 248:665-671.
26. Cardenas D.D., Ditunno J., Graziani V., et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord 2007, 45:158-168.
27. Hobart J.C., Riazi A., Lamping D.L., et al. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003, 60:31-36.
28. Zwibel H.L. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 2009, 26:1043-1057.
29. Smith K.J., McDonald W.I. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999, 354:1649-1673.
30. Evenhuis J., Agoston S., Salt P.J., et al. Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation. Br J Anaesth 1981, 53:567-570.
31. Uges D.R., Sohn Y.J., Greijdanus B., et al. 4-Aminopyridine kinetics. Clin Pharmacol Ther 1982, 31:587-593.
32. Blight A.R., Henney H.R. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 2009, 31:328-335.
33. 2009, Fampridine Pharmacokinetic Written Summary, NDA 22-250, Acorda Therapeutics Inc, Hawthorne, NY.
34. Rizzo M.A., Hadjimichael O.C., Preiningerova J., et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004, 10:589-595.
35. Henze T., Rieckmann P., Toyka K.V., et al. Symptomatic treatment of multiple sclerosis. Eur Neurol 2006, 56:78-105. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.
36. Goodin D.S., Frohman E.M., Garmany G.P., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [published correction appears in Neurology. 2002;59:480]. Neurology 2002, 58:169-178.
37. Integrated Summary of Safety: Fampridine-SR in Patients With Multiple Sclerosis 2009, NDA 22-250, Acorda Therapeutics Inc, Hawthorne, NY.
38. Smith W., Swan S., Marbury T., et al. Single-dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010, 50:151-159.
39. Bever C.T., Young D., Anderson P.A., et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994, 44:1054-1059.
40. Vollmer T., Blight A.R., Henney H.R. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther 2009, 31:2215-2223.
41. Vollmer T., Henney H.R. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I-II, open-label trial. Clin Ther 2009, 31:2206-2214.
42. Hayes K.C., Katz M.A., Devane J.G., et al. Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003, 43:379-385.
43. Schwid S.R., Petrie M.D., McDermott M.P., et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997, 48:817-821.
44. Davis F.A., Stefoski D., Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990, 27:186-192.
45. Van Diemen H.A., Polman C.H., van Dongen T.M., et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992, 32:123-130.
46. Van Diemen H.A., Polman C.H., Koetsier J.C., et al. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993, 16:195-204.
47. Romani A., Bergamaschi R., Candeloro E., et al. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler 2004, 10:462-468.
48. Rossini P.M., Pasqualetti P., Pozzilli C., et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001, 7:354-358.
49. Polman C.H., Bertelsmann F.W., van Loenen A.C., et al. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994, 51:292-296.
50. Goodman A., Brown T., Edwards K., et al. Interim analysis of open-label extension studies of sustained release fampridine in patients with multiple sclerosis [AAN Annual Meeting poster S01.008]. Neurology 2010, 74(Suppl 2):A101.
51. Spyker D.A., Lynch C., Shabanowitz J., et al. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980, 16:487-497.
52. Stork C.M., Hoffman R.S. Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol 1994, 32:583-587.
53. Pickett T.A., Enns R. Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med 1996, 3:382-385.
54. Johnson N.C., Morgan M.W. An unusual case of 4-aminopyridine toxicity. J Emerg Med 2006, 30:175-177.
55. Velez L., Shirazi F., Goto C., et al. Opisthotonic posturing with neuromuscular irritability attributable to 4-aminopyridine ingestion by a healthy pediatric patient. Pediatrics 2003, 111:e82-e84.
56. Smeets J.W., Kunst M.W. Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 1995, 139:2667-2669.
57. Burton J.M., Bell C.M., Walker S.E., et al. 4-Aminopyridine toxicity with unintentional overdosage in four patients with multiple sclerosis. Neurology 2008, 71:1833-1834.
58. De Cauwer H., De Wolf P., Couvreur F., et al. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy?. Acta Neurol Belg 2009, 109:40-41.
59. Badruddin A., Menon R.S., Reder A.S. 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology 2009, 72:1100-1101.
60. Food and Drug Administration Center for Drug Evaluation and Research, Pharmacy Compounding Advisory CommitteePharmacy Compounding Advisory Committee, Accessed June 9, 2008. http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3513t1.rtf.
61. Report: Limited FDA Survey of Compounded Drug Products Food and Drug Administration Center for Drug Evaluation and Research, Accessed January 28, 2008. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155725.htm.
62. Report: 2006 Limited FDA Survey of Compounded Drug Products Food and Drug Administration Center for Drug Evaluation and Research, Accessed September 6, 2010. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm204237.htm.
63. Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 2011, 41:51-54.
64. Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs US Food and Drug Administration, Accessed June 9, 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf.
65. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline 2006, Accessed April 5, 2012. http://www.ich.org/products/guidelines.html.
66. Nerbonne J.M. Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium. J Physiol 2000, 525(pt 2):285-298.
67. Han W., Wang Z., Nattel S. A comparison of transient outward currents in canine cardiac Purkinje cells and ventricular myocytes. Am J Physiol Heart Circ Physiol 2000, 279:H466-H474.
68. Sridhar A., da Cunha D.N., Lacombe V.A., et al. The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization. Br J Pharmacol 2007, 152:870-879.
69. Renganathan M., Sidach S., Blight A.R. Effects of 4-aminopyridine on cloned hERG channels expressed in mammalian cells. Arch Drug Info 2009, 2:51-57.
70. Thomas G., Klatt B., Blight A. Effect of 4-aminopyridine on action potential parameters in isolated dog Purkinje fibers. Arch Drug Info 2010, 3:19-25.
71. March B., Cardi T. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals. Expert Opin Investig Drugs 2009, 18:1807-1815.
72. Isoda W.C., Segal J.L. Effects of 4-aminopyridine on cardiac repolarization, PR interval, and heart rate in patients with spinal cord injury. Pharmacotherapy 2003, 23:133-136.
73. Spatt J., Chaix R., Mamoli B. Epileptic and non-epileptic seizures in multiple sclerosis. J Neurol 2001, 248:2-9.
74. Striano P., Orefice G., Brescia Morra V., et al. Epileptic seizures in multiple sclerosis: clinical and EEG correlations. Neurol Sci 2003, 24:322-328.
75. Koch M., Uyttenboogaart M., Polman S., et al. Seizures in multiple sclerosis. Epilepsia 2008, 49:948-953.
76. Kelley B.J., Rodriguez M. Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 2009, 23:805-815.
77. Sander J.W. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003, 16:165-170.
78. Wade D.T., Makela P.M., House H., et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006, 12:639-645.
79. Schuele S.U., Kellinhaus C., Shook S.J., et al. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005, 64:1086-1087.
80. Crayton H.J., Rossman H.S. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther 2006, 28:445-460.
81. Boissy A.R., Cohen J.A. Multiple sclerosis symptom management. Expert Rev Neurother 2007, 7:1213-1222.
82. Drugs That May Lower Seizure Threshold Accessed May 16, 2010. http://professionals.epilepsy.com/page/table_seniors_drugs.html.
83. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [published erratum appears in Ann Neurol. 1996;40:480]. Ann Neurol 1996, 39:285-294.
84. Ball A.P., Hopkinson R.B., Farrell I.D., et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 1979, 48:473-491.
85. Fountain N.B., Freeman J.M. EEG is an essential clinical tool: pro and con. Epilepsia 2006, 47(Suppl 1):23-25.
86. Eriksson M., Ben-Menachem E., Andersen O. Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler 2002, 8:495-499.
87. Ampyra (Dalfampridine) Extended Release Tablets. Risk Evaluation and Mitigation Strategy Acorda Therapeutics, Accessed August 6, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000REMS.pdf.
88. Avonex® [Interferon beta-1a] [prescribing information] October 2008, Biogen Idec Inc, Cambridge, MA.
89. Tysabri® [natalizumab] [prescribing information] 2010, Biogen Idec Inc, Cambridge, MA.